BELARA

Informació principal

  • Denominació comercial:
  • BELARA DIARIO 0,03/2 mg 28 comprimidos recubiertos (21+7)
  • formulario farmacéutico:
  • Comprimidos
  • Vía de administración:
  • Oral
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • BELARA DIARIO 0,03/2 mg 28 comprimidos recubiertos (21+7)
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 664787
  • última actualització:
  • 10-06-2018

Prospecte

BELARA DIARIO 0,03/2 mg 28 comprimidos

recubiertos (21+7)

etinilestradiol+clormadinona

Indicacions

Medicament utilitzat per evitar quedar embarassada (ANTICONCEPTIU).

Consideracions

Prengui els comprimits sencers, sense partir ni mastegar, empassant-los amb ajuda d'un got d'aigua.

Prengui aquest medicament sempre a la mateixa hora.

L'efic

cia anticonceptiva del preparat es pot veure redu

da si oblida la presa d'alguna de les dosis.

Si s'adona de l'oblit de la presa dins de les 12 hores seg

ents a l'hora habitual de la presa, ha de prendre

el comprimit immediatament i continuar el tractament normalment, prenent el seg

ent comprimit a

l'hora habitual. .

Si s'adona de l'oblit de la presa despr

s de les 12 hores seg

ents a l'hora habitual de la presa, ja no es

pot assegurar la protecci

anticonceptiva. Ha de prendre l'

ltim comprimit oblidat immediatament i

continuar el tractament fins a acabar l'env

s juntament amb altres m

todes de control de l'embar

fins a comen

ar el seg

ent env

Aquest medicament modifica l'acci

d'altres f

rmacs, NO prengui altres medicaments sense consultar

abans al seu metge o farmac

utic.

Efectes adversos

Interrompi immediatament el tractament i AVISI al seu metge si durant el tractament apareix mal de cap

fort i duratiu, visi

borrosa, augment de la tensi

arterial o sagnats irregulars.

Aquest medicament pot produir mol

sties gastrointestinals (n

usees, v

mits, etc.), dolor

abdominal i p

rdua de gana.

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Prengui 1 comprimit a l'esmorzar.

Prengui aquest medicament durant 28 dies al mes, sense cap dia de descans.

VIA ORAL.

3-11-2018

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM 1/35 and two lots of ORTHO-NOVUM 7/7/7 Due to Incorrect Veridate Dispenser Instructions

Janssen Pharmaceuticals, Inc. has initiated a voluntary recall of one lot of ORTHO-NOVUM 1/35 (norethindrone / ethinyl estradiol) Tablets and two lots of ORTHO-NOVUM 7/7/7 (norethindrone / ethinyl estradiol) Tablets to the pharmacy level. The patient information provided inside affected packages of ORTHO-NOVUM does not include the appropriate instructions for the Veridate dispenser.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves new vaginal ring for one year of birth control

FDA approves new vaginal ring for one year of birth control

FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration